egtazic acid has been researched along with olmesartan in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Felder, RA; Hashimoto, S; Jose, PA; Sanada, H; Watanabe, T; Yatabe, J; Yatabe, MS; Yoneda, M | 1 |
1 other study(ies) available for egtazic acid and olmesartan
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autocrine Communication; Cells, Cultured; Chelating Agents; Cytochalasin D; Egtazic Acid; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Hypertension, Renal; Imidazoles; Male; Mesangial Cells; MicroRNAs; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nucleic Acid Synthesis Inhibitors; Oxidative Stress; Paracrine Communication; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stress, Mechanical; Tetrazoles; Vasoconstrictor Agents | 2009 |